6 Doctor-Supervised GLP-1 Programs Actually Worth the Money in 2026
The telehealth weight-loss market looks different than it did eighteen months ago. A March 2026 settlement between Novo Nordisk and several compounding suppliers pushed many platforms off compounded semaglutide entirely, FDA warning letters landed at more than thirty telehealth and pharmacy operations early in the year, and Lilly began offering oral orforglipron through LillyDirect at roughly $149 a month, a price disclosed in an April 2026 company announcement. People shopping for a GLP-1 program right now are asking sharper questions than before: Who dispenses this? What’s in the vial? What does a month actually cost?
Forums and patient communities keep surfacing the same short list of providers, usually for one of three reasons: low cash price with real physician oversight, verifiable pharmacy sourcing, or a serious coaching layer around the medication. The six programs below cover all three themes.
1. HealthRX
Price is where this one separates itself. Compounded semaglutide starts at $99 a month and compounded tirzepatide at $149, both once-weekly injections, both with free overnight shipping to all fifty states. Most cash-pay telehealth programs charge noticeably more for the same compound class.
The pharmacy sourcing is specific and checkable. Medication ships from Manifest Pharmacy in Greer, South Carolina, a 503A-licensed, USP-797-compliant compounding facility. Lots are tracked from bench to delivery. The platform carries a LegitScript certification (certificate number 50087439), which involves third-party verification of legal and safety standards. That’s more transparency than most providers publish without being asked.
The process: complete an online health assessment, a U.S. board-certified physician reviews it within roughly twenty-four hours, and the medication ships overnight once approved. No drawn-out onboarding.
One honest note. These are compounded medications, not FDA-approved drugs. The efficacy numbers HealthRX references in its materials come from the SURMOUNT-1 trial (about 21% body weight reduction at 72 weeks for tirzepatide) and the STEP 1 trial (roughly 15% at 68 weeks for semaglutide). Those are trial results for the branded molecules, not company claims.
For straightforward, cash-pay GLP-1 access with a traceable pharmacy and low monthly pricing, this is the most defensible pick on the list right now.
2. FormBlends
This one earns its spot for a different reason than price. FormBlends publishes actual purity documentation per product: HPLC purity percentages, mass spectrometry identity confirmation, endotoxin and sterility results. Named numbers, not just a statement that testing happened. Few GLP-1 telehealth providers go that far.
Compounded semaglutide runs around $299 and tirzepatide around $349, so the cost is higher than HealthRX’s entry pricing. The tradeoff is a detailed paper trail on what’s in the vial and a notably wider catalog. FormBlends carries peptides beyond GLP-1s, including compounds marketed for recovery, longevity, and cognitive support, all under the same clinician oversight model. Medication ships to 47 states from an FDA-registered 503A compounding pharmacy.
The right choice here is someone who wants independently documented purity data, or who wants to consolidate GLP-1 treatment and other peptide protocols under one provider, and is willing to pay for that.
3. Mochi Health
Mochi leans into the clinical side harder than most. The platform staffs board-certified obesity medicine physicians rather than general practitioners, which matters when someone has a complicated metabolic history or has failed other weight-loss approaches before.
Compounded semaglutide is priced at $99 a month and tirzepatide at $199. There’s more ongoing monitoring baked into the model than you’d get from faster-turnaround services. It ships to a broad footprint but not all fifty states in every case. People who want actual obesity-medicine expertise in the loop, not just a prescription review, consistently recommend Mochi in patient communities.
4. Hims & Hers
Hims & Hers exited compounded GLP-1s after the March 2026 Novo settlement and moved to branded medications. Injectable Wegovy runs roughly $299 a month through the platform, oral options around $249, and Zepbound approximately $399. With insurance and applicable savings cards, some patients get to $0 to $25 a month.
That pricing depends entirely on insurance coverage coming through. Cash-pay patients without a good plan are looking at significantly higher out-of-pocket costs than the compounded options on this list. The brand’s scale does mean a polished app experience and reliable customer support infrastructure. Worth considering if insurance coverage is in play.
5. Ro Body
Ro charges about $39 for the first month, then $74 to $149 a month for the membership, with medications billed separately on top of that. The platform has a dedicated prior-authorization team that handles the insurance paperwork for branded GLP-1s, which is genuinely useful given how time-consuming prior auth can be.
The membership-plus-meds-separate pricing structure means the actual monthly cost varies a lot depending on which medication gets approved and whether insurance covers it. Factor that in before comparing Ro’s listed price to an all-in cash-pay quote.
6. Form Health
The premium end of the market. Form Health charges around $299 a month and includes labs and medication in addition to access to both an MD and a registered dietitian. It’s a real multi-disciplinary program, not just prescription management.
That price point is too high for most people, and not everyone needs the dietitian layer. But for someone coming off multiple failed attempts who wants the most clinically intensive approach available through telehealth, Form Health is the program most consistently recommended in that context. It’s also worth noting that the dietitian involvement differentiates it from nearly everything else on this list.
A Few Honest Notes Before Choosing
Compounded GLP-1 medications are not FDA-approved drugs. Pharmacy quality varies widely across the telehealth space, and the FDA’s 2026 warning letters to more than thirty providers are a real signal to verify sourcing before committing. Ask any provider which pharmacy fulfills your prescription and whether it holds 503A accreditation.
Insurance coverage changes the math entirely for branded medications. Cash-pay compounded options are worth comparing on total monthly cost, not just headline price.
| Provider | Approx. Monthly Cost | Medication Type | Key Differentiator |
| HealthRX | From $99 (sema) / $149 (tirz) | Compounded | Named 503A pharmacy, overnight shipping, low price |
| FormBlends | ~$299 (sema) / ~$349 (tirz) | Compounded | Published purity testing, peptide catalog |
| Mochi Health | $99 (sema) / $199 (tirz) | Compounded | Obesity medicine physicians |
| Hims & Hers | $249-$399 (branded) | Branded | Insurance pathway, scale |
| Ro Body | $39-$149 + meds | Branded/compounded | Prior-auth support |
| Form Health | ~$299 all-in | Branded/Rx | MD + dietitian, labs included |
Common Questions
Which of these programs is safest to use now that the FDA has issued warning letters to compounding operations?
Safety depends heavily on where your medication is made. Programs that name their compounding pharmacy and confirm 503A licensure and USP-797 compliance, as HealthRX does with Manifest Pharmacy and FormBlends does with its FDA-registered facility, give you something checkable. The warning letters targeted providers that could not or would not document sourcing. Ask directly before you pay.
Does Hims & Hers still offer compounded semaglutide, or did the Novo settlement end that?
Hims & Hers exited compounded GLP-1s after the March 2026 Novo Nordisk settlement and shifted entirely to branded medications including Wegovy and Zepbound. Patients who were on compounded semaglutide through the platform had to transition. The branded pricing runs $249 to $399 a month without insurance coverage.
Is there a meaningful clinical difference between getting a general practitioner versus an obesity medicine specialist through one of these platforms?
For uncomplicated cases, probably not much. For patients with metabolic conditions, prior failed attempts, or medications that interact with GLP-1s, the difference can be real. Mochi Health specifically staffs board-certified obesity medicine physicians, and Form Health pairs an MD with a registered dietitian, which is a meaningfully different clinical model than a standard prescription review.
How does FormBlends justify charging $299 or more when HealthRX starts at $99 for the same compound class?
The price gap reflects what’s published, not just what’s promised. FormBlends provides HPLC purity percentages, mass spectrometry identity confirmation, and endotoxin and sterility results per product lot. That documentation costs money to produce. If you want a paper trail on exactly what is in the vial, that’s the tradeoff. If price is the priority and you trust the 503A certification model, HealthRX is harder to beat.
Does Ro Body’s membership fee get charged on top of medication costs, and how does that affect the real monthly total?
Yes, the membership and medication are billed separately. The membership runs $39 for month one, then $74 to $149 monthly after that, with branded GLP-1 costs added on top depending on what insurance approves. Ro’s prior-authorization support can reduce the medication cost substantially for patients with coverage, but cash-pay patients face a higher combined total than Ro’s headline membership price suggests.
Sources
- FDA warning letters to telehealth and compounding firms, early 2026 (FDA.gov official enforcement actions)
- Novo Nordisk settlement announcement, March 9 2026 (Reuters, Novo Nordisk press release)
- SURMOUNT-1 trial results, tirzepatide (NEJM, 2022)
- STEP 1 trial results, semaglutide (NEJM, 2021)
- Eli Lilly orforglipron direct-to-patient pricing disclosure, April 2026 (Eli Lilly press release)
- LegitScript certification database (LegitScript.com)
- Individual provider pricing pages verified against publicly listed rates, 2026